May 10, 2018 PR/Corporate

Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PDF Version SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted equity awards effective as of May 8, 2018, under Fluidigm’s 2017 Inducement Award Plan (Plan), as a material inducement to three individuals entering into employment with Fluidigm. The equity... Read more

April 23, 2018 PR/Corporate

Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations

PDF Version SOUTH SAN FRANCISCO, Calif., April 23, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Brad Kreger as Senior Vice President, Global Operations. In this role, Kreger leads global manufacturing, supply chain, demand planning, and distribution for Fluidigm. As a member of the executive leadership team reporting to President and CEO Chris Linthwaite, Kreger will be responsible for... Read more

April 13, 2018 Cell Analysis Tools Product Launch

Fluidigm Introduces High-Parameter Maxpar Immune Monitoring Panel for Translational and Clinical Research

PDF Version Providing the industry’s first commercially available high-parameter immune monitoring solution for deep profiling of PBMC, Fluidigm brings proven mass cytometry together with innovative third-party data analysis SOUTH SAN FRANCISCO, Calif., April 13, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Maxpar® Human Immune Monitoring Panel Kit for comprehensive immune cell profiling in... Read more

April 12, 2018 Life Science Tools Product Launch

Fluidigm Releases CFTR Next-Generation Sequencing Library Prep Assay for Use With the Juno System

PDF Version SOUTH SAN FRANCISCO, Calif., April 12, 2018 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Advanta™ CFTR NGS Library Prep Assay, a highly efficient and scalable next-generation sequencing (NGS) library prep workflow for sequencing of the CFTR (cystic fibrosis transmembrane conductance regulator) gene. Cystic fibrosis (CF) is a complex, multisystem disease that is... Read more

October 18, 2017 Clinical Research/Diagn. Product Launch

Fluidigm to Unveil High-Parameter Tissue Imaging System

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced that it will unveil a commercially available system for high-parameter tissue imaging on Tuesday, October 24, 2017, via a global livestream video. This new imaging system significantly expands the number of protein biomarkers that can be simultaneously detected from tissues and tumors as compared to... Read more

August 17, 2017 Life Science Tools M&A, Partnerships

Fluidigm Licenses CFTR Next-Generation Sequencing Assay From Baylor Genetics for Use With the Juno System

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2017 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) and Baylor Genetics today announced that they have entered into a licensing agreement to offer a next-generation sequencing (NGS) library prep assay that enables efficient sequencing of the CFTR (cystic fibrosis transmembrane conductance regulator) gene. Under the agreement, Fluidigm obtains the rights to commercialize the CFTR library prep... Read more

August 10, 2017 PR/Corporate

Fluidigm Announces Sale of $30 Million of Common Stock in At-The-Market Equity Offering

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced the sale of 9,090,909 shares of its common stock for aggregate gross proceeds of approximately $30.0 million before commissions and offering expenses under its previously announced “at-the-market” equity offering program. The sales were completed pursuant to the Sales Agreement between the company and Cowen and Company, LLC,... Read more

July 27, 2017 Clinical Research/Diagn. M&A, Partnerships

Fluidigm and Ascendas Genomics Announce Strategic Partnership to Develop Microfluidic Molecular Diagnostics in China

SOUTH SAN FRANCISCO, Calif. and ZHONGSHAN, China, July 27, 2017 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) and Ascendas Genomics today announced a strategic partnership to develop molecular diagnostics in China. Under the terms of the partnership, Ascendas Genomics will develop and commercialize molecular diagnostic systems and assays in China using microfluidic technologies included in the Fluidigm® Biomark™ HD and Juno™ systems. Fluidigm’s microfluidic technology enables... Read more

July 18, 2017 Life Science Tools Product Launch

Fluidigm Introduces Immuno-Oncology Gene Expression Assay for Translational and Clinical Research

Advanta Immuno-Oncology Gene Expression Assay enables efficient screening of 170 highly informative genes involved in human checkpoint therapeutic response SOUTH SAN FRANCISCO, Calif., July 18, 2017 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced the launch of the Advanta™ Immuno-Oncology Gene Expression Assay, an optimized qPCR assay that enables efficient interrogation of tumor immunobiology using proven Fluidigm® microfluidic technology.... Read more

March 27, 2017 PR/Corporate

Nicolas Barthelemy and Carlos Paya Join Fluidigm Board of Directors

SOUTH SAN FRANCISCO, Calif., March 27, 2017 – Fluidigm Corporation (NASDAQ:FLDM) today announced that Nicolas Barthelemy and Dr. Carlos Paya have been appointed to its Board of Directors. Barthelemy brings over 25 years of health care industry experience to the Fluidigm Board, having served in multiple senior executive roles in the biopharmaceutical, life science tools,... Read more